Doxorubicin

interleukin 1 alpha ; Homo sapiens







14 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35551917 Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation. 2022 Jul 2
2 33952842 [Doxorubicin directly induced fibrotic change of cardiac fibroblasts]. 2021 2
3 34120620 Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. 2021 Jun 13 1
4 34145895 Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity. 2021 Jun 18 1
5 34547383 Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production. 2021 Dec 1 1
6 25275022 Differential expression of VEGF and IL-1alpha after photodynamic treatment in combination with doxorubicin or taxotere. 2014 Oct 2
7 20599921 Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. 2010 Sep 25 3
8 12415617 Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. 2002 Jan-Feb 1
9 7803193 A recombinant human interleukin-1 beta protects adriamycin-induced toxicity. Adriamycin cardiotoxicity and interleukin-1. 1993-1994 3
10 8317554 Age-dependent basal level and induction capacity of copper-zinc and manganese superoxide dismutase and other scavenging enzyme activities in leukocytes from young and elderly adults. 1993 Jul 1
11 8453624 Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice. 1993 Apr 1 2
12 8512591 Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3). 1993 May 25 4
13 1292755 Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells. 1992 7
14 2565969 Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage proteoglycan resorption in-vitro. 1989 Jan 4